You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

activating mutation

Showing 1 - 25 of 3,282
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Aumolertinib, Anlotinib, TP53 Trial (Aumolertinib,Anlotinib)

Not yet recruiting
  • Aumolertinib
  • +4 more
  • (no location specified)
Mar 8, 2023

NSCLC, EGFR Activating Mutation, Brain Metastases Trial in Beijing (TY-9591, Osimertinib)

Not yet recruiting
  • NSCLC
  • +2 more
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospitial,Chinese Academy of Medic
Jul 9, 2023

Brain Metastases, Radiotherapy, EGFR Activating Mutation Trial in Guangdong (brain radiotherapy, Almonertinib)

Recruiting
  • Brain Metastases
  • +2 more
  • Guangdong, Guangzhou, China
    Sun-Yat-Sen university
Mar 13, 2023

Non-squamous Non-small-cell Lung Cancer, Stage IV NSCLC, ROS1 Gene Rearrangement Trial in Toronto (Crizotinib)

Recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • +4 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jan 8, 2023

NSCLC, EGFR Activating Mutation Trial in Changsha, Shanghai (TY-9591, Osimertinib, Osimertinib)

Recruiting
  • NSCLC
  • EGFR Activating Mutation
  • Changsha, Hunan, China
  • +1 more
Dec 6, 2022

Lung Cancer, NSCLC, PD-L1 Gene Mutation Trial in Detroit (Durvalumab, Carboplatin, Pemetrexed)

Withdrawn
  • Lung Cancer
  • +3 more
  • Detroit, Michigan
    Henry Ford Health System
Feb 15, 2022

NSCLC, EGFR Activating Mutation Trial in Guangzhou (Sintilimab, Carboplatin, Nab paclitaxel)

Recruiting
  • Non-small Cell Lung Cancer
  • EGFR Activating Mutation
  • Sintilimab
  • +2 more
  • Guangzhou, Guangdong, China
    Guangdong Lung Cancer Institute, Guangdong Provincial People's H
Aug 8, 2022

NSCLC (NSCLC) Trial in Jinan (WX-0593 Tablets, chemo, Thoracic Radiation Therapy(TRT))

Recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • WX-0593 Tablets
  • +2 more
  • Jinan, Shandong, China
    Shandong Cancer Hospital and Institute
Apr 24, 2022

NSCLC, EGFR Activating Mutation, Brain Metastases Trial in Beijing (TY-9591 Tablets)

Recruiting
  • NSCLC
  • +3 more
  • TY-9591 Tablets
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospitial,Chinese Academy of Medic
May 14, 2022

KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer Trial in Saint Louis (avutometinib (VS-6766) and defactinib in

Recruiting
  • KRAS Activating Mutation
  • +4 more
  • avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 3, 2023

Activating ALK Gene Mutation Negative, Activating EGFR Gene Mutation Negative, Activating ROS1 Gene Mutation Negative Trial in

Completed
  • Activating ALK Gene Mutation Negative
  • +7 more
  • Counseling
  • +2 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Sep 7, 2022

Lung Cancer, Lung Adenocarcinoma, EGFR Activating Mutation Trial in Vandoeuvre-lès-Nancy (Collection of surgical waste)

Enrolling by invitation
  • Lung Cancer
  • +4 more
  • Collection of surgical waste
  • Vandoeuvre-lès-Nancy, Lorraine, France
    Seitlinger
Nov 24, 2021

Lung Tumor Malignant, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-451)

Recruiting
  • Lung Neoplasm Malignant
  • +18 more
  • Fairfax, Virginia
    New Experimental Therapeutics of Virginia (NEXT Oncology)
Mar 29, 2022

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8 Trial in Houston

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 25, 2022

Non Small Cell Lung Cancer, KRAS Activating Mutation Trial in United States (VS-6766 and sotorasib)

Recruiting
  • Non Small Cell Lung Cancer
  • KRAS Activating Mutation
  • avutometinib (VS-6766) and sotorasib
  • Washington, District of Columbia
  • +6 more
Jan 31, 2023

NSCLC, Stage IV, NSCLC Stage IIIB, NSCLC, Stage IIIC Trial in Canada, Hong Kong, United States (tarloxotinib bromide)

Terminated
  • NSCLC, Stage IV
  • +7 more
  • tarloxotinib bromide
  • Irvine, California
  • +13 more
Nov 11, 2021

Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer Trial in United States (VS-6766 and adagrasib)

Recruiting
  • Non Small Cell Lung Cancer
  • +5 more
  • avutometinib (VS-6766) and adagrasib
  • San Francisco, California
  • +4 more
Dec 21, 2022

Nsclc, EGFR Activating Mutation, EGF-R Positive NSCLC Trial in Hong Kong (Pembrolizumab, Lenvatinib, Pemetrexed)

Recruiting
  • Nsclc
  • +5 more
  • Hong Kong, Hong Kong
    Queen Mary Hospital
Nov 25, 2021

Activated PI3Kdelta Syndrome (APDS); PASLI Disease Trial in Worldwide (CDZ173)

Active, not recruiting
  • Activated PI3Kdelta Syndrome (APDS); PASLI Disease
  • Bethesda, Maryland
  • +7 more
Jul 22, 2022

NSCLC With EGFR-Activating Mutations Trial in Worldwide (Dacomitinib (PF-00299804), Gefitinib)

Completed
Has Results
  • Non-small Cell Lung Cancer With EGFR-Activating Mutations
  • Beijing, China
  • +51 more
Feb 10, 2022

Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer Trial in United States (Ulixertinib (BVD-523))

Available
  • Pancreatic Cancer
  • +20 more
  • Ulixertinib (BVD-523)
  • Birmingham, Alabama
  • +25 more
Nov 4, 2022

Lung Tumor, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-701, osimertinib, carboplatin)

Recruiting
  • Lung Neoplasm
  • +26 more
  • Boston, Massachusetts
  • +6 more
Jun 23, 2022

RAS Mutation, NRAS Gene Mutation, Melanoma Trial in Phoenix, Newnan, Zion (OKI-179 + binimetinib)

Recruiting
  • RAS Mutation
  • +2 more
  • OKI-179 + binimetinib
  • Phoenix, Arizona
  • +4 more
Sep 22, 2022

NSCLC, Leptomeningeal Metastases, Brain Metastases Trial in United States (Tesevatinib)

Completed
Has Results
  • Non-Small Cell Lung Cancer
  • +2 more
  • Beverly Hills, California
  • +6 more
Mar 7, 2022

Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19 Trial in France (Plasma ctDNA, FFPE blocks)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +3 more
  • Plasma ctDNA
  • FFPE blocks
  • Angers, France
  • +35 more
Sep 19, 2023